Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.

摘要: K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies. Nevertheless 70% 40% of these patients still does not seem benefit from this therapeutic approach. FISH EGFR GCN has been previously demonstrated correlate with clinical outcome cancer treated CISH also seemed able provide accurate information the advantage a simpler and reproducible technique involving immunohistochemistry light microscopy. Based on findings we investigated correlation between both in wild-type irinotecan-cetuximab. Patients advanced wild-type, receiving irinotecan-cetuximab after failure irinotecan-based chemotherapy were eligible. A cut-off value for 2.6 2.12 respectively was derived ROC curve analysis. Forty-four available We observed partial remission 9 (60%) 2 (9%) cases ≥ < (p = 0.002) 10 (36%) 1 (6%) 0.03). Median TTP 7.7 6.4 months showing increased whereas it 2.9 3.1 those low 0.04 0.02 respectively). may represent effective tools further selection cetuximab.